Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Factors Affecting Protein-Drug Binding: Drug Interactions

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Drug Binding to Blood Components

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness of hypnosis on pain and anxiety in dentistry: Narrative review.

The American journal of clinical hypnosis·2022

Same author

Study on the interaction of three classical drugs used in psychiatry in albumin through spectrofluorimetric modeling.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2021

Same author

Application of Aptamer-Based Assays to the Diagnosis of Arboviruses Important for Public Health in Brazil.

International journal of molecular sciences·2020

Same author

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.

Pharmaceutics·2020

Same author

A screening test based on hematological and histological biomarkers to evaluate the environmental impacts in tambaqui (Colossoma macropomum) from a protected area in Maranhão, Brazilian Amazon.

Chemosphere·2018

Same author

Relevance of Hydrodynamic Effects for the Calculation of Outer Surface Potential of Biological Membrane Using Electrophoretic Data.

Anais da Academia Brasileira de Ciencias·2016

Search research articles

Related Experiment Videos

Risperidone interacts with serum albumin forming complex.

Viviane Muniz Fragoso¹, Dilson Silva, Frederico Alan de Oliveira Cruz

¹Program Graduate in Clinical and Experimental Physiopathology, Rio de Janeiro State University, Brazil.

Environmental Toxicology and Pharmacology

|January 17, 2012

Summary

This study investigated how risperidone interacts with human and bovine serum albumin using fluorescence quenching. Risperidone binds to albumin, forming a complex, with binding affinity varying by temperature and albumin type.

Related Experiment Videos

Area of Science:

Biochemistry
Pharmacology
Spectroscopy

Background:

Risperidone is an atypical antipsychotic medication.
Serum albumin serves as a primary drug transport protein in the bloodstream.
Understanding drug-protein interactions is crucial for pharmacokinetics and pharmacodynamics.

Purpose of the Study:

To elucidate the binding mechanisms between risperidone and human serum albumin (HSA) and bovine serum albumin (BSA).
To quantify the binding affinity and explore the binding site of risperidone on serum albumin.

Main Methods:

Fluorescence quenching spectroscopy was employed to monitor risperidone-albumin interactions.
Selective excitation of tryptophan residues at 290 nm was utilized.
Stern-Volmer analysis was performed to determine quenching constants and association constants.

Main Results:

Risperidone induced fluorescence quenching of both HSA and BSA, indicating complex formation.
Association constants were determined, showing temperature-dependent binding affinity.
BSA exhibited higher quenching intensity than HSA, suggesting differential binding interactions.

Conclusions:

Risperidone forms a complex with serum albumin.
The binding affinity is influenced by temperature and the specific albumin.
Results suggest a potential primary binding site for risperidone within sub-domain IB of albumin.